Kelley Shannon T, the General Counsel of Madrigal Pharmaceuticals, Inc., has sold 1,077 shares of the company's common stock. This transaction, which took place on November 6, 2026, is part of a pre-established trading plan, reflecting a strategic approach to stock management.

The sale is notable as it occurs within the context of the pharmaceutical industry, where companies are continually adapting to market changes and investor expectations. Such transactions can influence investor sentiment regarding Madrigal Pharmaceuticals and its peers.

Background

Madrigal Pharmaceuticals, Inc. is a company incorporated in Delaware and operates in the pharmaceutical preparations sector. The firm is publicly traded under the ticker symbol MDGL. Its recent filings indicate a consistent pattern of transactions involving key personnel, including Kelley Shannon T.

What the Filing Says

According to the recent SEC filing (accession number 0001628280-26-071744), Kelley Shannon T sold 1,077 shares at a price of $400 per share. Following this transaction, Shannon owns 10,397 shares of Madrigal Pharmaceuticals.

Impact

This sale may affect investor perceptions of Madrigal Pharmaceuticals, particularly as it reflects the actions of a senior officer within the company. Such transactions can often be scrutinized by investors looking for insights into the company's future performance.

What's Next

The filing does not say what happens next.